Wpd Pharmaceuticals Inc · CSE:WBIO
Wpd Pharmaceuticals — Investor Presentation (October 2020)
37 slides from Wpd Pharmaceuticals's investor presentation, October 2020
Slide 1: WPD Pharmaceuticals Investor Presentation
WPD Pharmaceuticals OCTOBER 2020 | INVESTOR PRESENTATION CSE:WBIO Investor Presentation | CSE:WBIO |
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words "believe",
Slide 3: Company Overview
Company WPD Pharmaceuticals is a diverse biotech company that has 10 novel drug candidates with 4 in clinical development stage via its development partners. Overview WPD drug candidates are in collaboration via its development partners with institutions including MD Anderson Cancer Center, Mayo Cli
Slide 4: Investment Highlights
Investment Highlights Experienced Management & Robust Drug Portfolio Strategic Collaborations Advisors 10 novel drug candidates across Team of scientists with extensive 5 indications Wake Forest University Health pharmaceutical experience Sciences, Moleculin Biotech Inc. and CNS Pharmaceuticals, Inc
Slide 5: World-Class Pharmaceutical Team
Word-Class Pharmaceutical Team Investor Presentation | CSE:WBIO | 5
Slide 6: Management Team
Mariusz Olejniczak Beata Pająk CHIEF EXECUTIVE OFFICER CHIEF SCIENTIFIC OFFICER Mariusz Olejniczak, CEO of WPD Pharmaceuticals is an Beata Pajak, DSc, PhD is a biotechnologist with experienced professional in medicinal products, medical experience in the field of medical biology, devices, supplement
Slide 7: Scientific Advisory Board
Scientific Advisory Board Dr. Sigmund Hsu SCIENTIFIC ADVISORY BOARD Dr. Waldemar Priebe FOUNDER, CHAIRMAN OF SCIENTIFIC Dr. Tomasz Skorski ADVISORY BOARD SCIENTIFIC ADVISORY BOARD Dr. Waldemar Priebe, Ph.D., is a world renowned medicinal chemist and entrepreneur. Dr. Priebe is a Professor of Medicin
Slide 8: 10 Drugs 5 Indications
10 Drugs 5 Indications Investor Presentation | CSE:WBIO | 8
Slide 9: Drug Pipeline by Indication
Discovery Pre-Clinical Regulatory Clinical I / II Brain Cancers WPD101 Berubicin WP1066 Pancreatic Cancers WP1122 WP1066 WP1234 WP1732 Other Cancers WPD103 Annamycin WP1220 Melanoma WPD102 Investor Presentation | CSE:WBIO | 9
Slide 10: WPD101 - Indications to Treat Brain Cancers including Glioblastoma
WPD101 - Indications to Treat Brain Cancers including Glioblastoma OVERVIEW The breakthrough of the solution is based on the use of GBM-targeted therapy against IL-13RA2 and EphA2 - brain tumor-specific receptors conjugated with bacterial cytotoxins. It is well known, that interluekin-13 receptor al
Slide 11: WPD101 Current Status and License
WPD101 CURRENT STATUS WPD101 is currently in the preclinical stage of development. Its consistent anticancer properties are demonstrated and validated in dogs with spontaneous GBM closely resembling GBM in human patients. Overall, results of the research indicate significant potential of WPD101 demo
Slide 12: WPD101 Funding
WPD101 FUNDING In February 2018, WPD received a grant from the European Union, under the European Regional Development Fund, the Smart Growth Operational Program 2014-2020, implemented under the National Center for Research and Development in Poland (NCBiR) for the development of WPD101 that would i
Slide 13: WPD102 - Indications to Treat Uveal Melanoma
WPD102 - Indications to Treat Uveal Melanoma OVERVIEW Uveal melanoma (UM), a rare but deadly cancer of the eye that often rapidly progresses to the liver is characterized by the expression of the tumor-specific receptors IL-13RA2. The breakthrough of WPD Pharmaceuticals’ solution will be based on th
Slide 14: WPD102 Clinical Development and License
WPD102 CLINICAL DEVELOPMENT WPD102 is currently in preclinical development and based on the data obtained from in vitro studies using cancer cell lines, we see significant potential for WPD102 for the treatment of uveal melanoma in humans. A Phase I clinical trial is expected to begin in 2021-22. LI
Slide 15: WPD103 - Indications to Treat GBM, Melanoma, & Other Cancers
WPD103 - Indications to Treat GBM, Melanoma, & Other Cancers OVERVIEW WPD103 is a radiopharmaceutical that is expected to be a new diagnostic tool and targeted therapy drug. In cooperation with Institute of Nuclear Chemistry and Technology, WPD Pharmaceuticals is going to submit grant proposal to Na
Slide 16: WPD103 Clinical Development and License
WPD103 CLINICAL DEVELOPMENT WPD103 is currently in preclinical development and based on the data obtained from in vitro studies using cancer cell lines and WPD101 in spontaneous GBM dog model studies, we see significant potential for WPD103 in diagnostics and therapy in humans. Phase I clinical tria
Slide 17: Berubicin - Indications to Treat Glioblastoma
BERUBICIN - Indications to Treat Glioblastoma OVERVIEW Berubicin (BER) is a new anthracycline proven to be able to reach brain tumors by crossing the blood brain barrier (BBB) (Inge et al., 2004). Thanks to this unique property, BER is a drug developed in the treatment of glioblastoma multiforme (GB
Slide 18: Berubicin Clinical Development
BERUBICIN CLINICAL DEVELOPMENT WPD Pharmaceuticals conducts research related to the development of the WPD104 molecule - berubicin, as a novel drug in glioblastoma multiforme (GBM) therapy for children and adult patients, as a part of the project “New approach to glioblastoma treatment addressing th
Slide 19: Berubicin Funding
BERUBICIN FUNDING On January 31, 2019, WPD received notice that it had been awarded a conditional grant in the amount of 22,033,066 PLN (CDN$7,625,287 as at July 22, 2019) from the European Union’s Regional Development Fund (“EURDF”) under the Smart Growth Operational Program 2014-2020, Sectoral Pro
Slide 20: Annamycin - Indications to Treat AML, Metastasis to Lungs
ANNAMYCIN - Indications to treat AML, metastasis to lungs OVERVIEW Annamycin is a derivative of doxorubicin, which, due to its high affinity for the cell membrane of liposomes, facilitates rapid penetration of the drug and effective delivery of Annamycin to cancer cells, effectively limiting adverse
Slide 21: Annamycin Funding, Affiliations & License
ANNAMYCIN FUNDING WPD Pharmaceuticals already submitted grant proposal to National Center of Research and Development in Poland (NCBiR) for phase I clinical studies of Annamycin in combination with cytarabine in AML patients. AFFILIATIONS & LICENSE On February 19, 2019, WPD entered into a sublicense
Slide 22: WP1066 - CNS Tumors, Pancreatic Cancer, Ocular Tumors
WP1066 - Indications to Treat CNS tumors, Pancreatic cancer, Ocular tumors OVERVIEW WP1066 represents a new class of drugs, which WPD calls “Immune/Transcription Modulators”. WP1066 demonstrated the ability to directly induce apoptosis but also the ability to stimulate an immune response to tumors a
Slide 23: WP1066 Grants / Funding
WP1066 GRANTS / FUNDING WPD plans submitting a grant proposal in the Q3/Q4/2020 for the use of WP1066 in the GBM. This grant is expected to provide an additional $7 million in the next 48 months to cover 70-80% of the costs of Phase I clinical trial for WP1066 and related analogs. WPD’s expected cos
Slide 24: WP1066 Affiliations & License
WP1066 AFFILIATIONS & LICENSE On February 19, 2019, WPD entered into a sublicense agreement (the “Moleculin Sublicense Agreement”) with Moleculin Biotech, Inc. (“Moleculin”) and supplementary agreements later, under which Moleculin sublicensed certain intellectual property rights to WPD, including r
Slide 25: WP1220 - Indications for Cutaneous T-cell Lymphoma
WP1220 - Indications for cutaneous T-cell lymphoma OVERVIEW WP1220 is an inhibitor of phosphor (p)-STAT3, activated form of a transcription factor, which is key for cancer cell growth and survival. Increased activity of p-STAT3 has been demonstrated in patients with CTCL. WP1220 is an analog compoun
Slide 26: WP1220 Clinical Development
WP1220 CLINICAL DEVELOPMENT In February 2020, data form phase Ib clinical study of WP1220 in CTCL patients in Poland were obtained. To evaluate the safety and efficacy of WP1220, compound was applied topically to subjects in stage I, II or III Mycosis Fungoides over 12 weeks (three 28-day cycles) of
Slide 27: WP1220 Partners, Affiliations & License
WP1220 PARTNERS, AFFILIATIONS & LICENSE On February 19, 2019, WPD entered into a sublicense agreement (the “Moleculin Sublicense Agreement”) with Moleculin Biotech, Inc. (“Moleculin”) and supplementary agreements later, under which Moleculin sublicensed certain intellectual property rights to WPD, i
Slide 28: WP1732 - Indications to Treat Pancreatic Cancer
WP1732 - Indications to Treat Pancreatic Cancer OVERVIEW The WP1732 is a new fully water-soluble p-STAT3 inhibitor, technology, which is complementary to orally bioavailable non-water soluble WP1066. Based on preclinical testing, WP1732 is a potential breakthrough discovery. STAT3 inhibitors are an
Slide 29: WP1732 Affiliations & License
WP1732 - Indications to Treat Pancreatic Cancer AFFILIATIONS & LICENSE On February 19, 2019, WPD entered into a sublicense agreement (the “Moleculin Sublicense Agreement”) with Moleculin Biotech, Inc. (“Moleculin”) and supplementary agreements later, under which Moleculin sublicensed certain intelle
Slide 30: WP1122 - Indications to Treat SARS-CoV-2 Infection
WP1122 - Indications to Treat SARS-CoV-2 Infection OVERVIEW SARS-CoV-2, similarly to other coronaviruses (such as SARS-CoV-2, MERS) upregulates glycolysis process in infected cells to generate ATP necessary for fast virus replication (Thanker et al., 2019; Wang et al., 2014). Thus, inhibition of gly
Slide 31: WP1122 Grants / Funding
WP1122 GRANTS / FUNDING WPD is going to submit a grant proposal to National Center for Research and Development in Poland (NCBiR) for the development of WP1122 that would include Phase I clinical studies. Management expects this grant to cover 70 – 80% of all research and development costs for the n
Slide 32: Corporate Overview - Capital Structure
Corporate Overview WPD Pharmaceuticals Inc. Capital Structure Issued and Outstanding 111,520,388 CSE: WBIO Warrants Fully Diluted 3,949,997 115,470,385 Management and Insider holdings 36% Investor Presentation | CSE:WBIO | 32
Slide 33: Contact
Contact Vancouver Office Warsaw Office Suite 1080 Żwirki i Wigury 101 789 West Pender St 02-089 Warszawa Vancouver, BC V6C 1H2 Poland wpdpharmaceuticals.com CSE:WBIO Investor Presentation | CSE:WBIO |
Slide 34: Appendix / References
Appendix / References: 1. Bojkova D., Klann K., Koch B., Widera M., Krause D., Ciesek S., Cinatl J., Munch C. Proteomics of SARS-CoV-2-infected host cells reveals therapy genes. Nature 2020, 583:469-472. 2. Brooks TA, O’Loughlin KL., Minderman H., Bundy BN., Ford LA., Vredenburg MR., Bernacki RJ., P
Slide 35: References
References: 15. Inge TH., Harris NL., Wu J., Azizkhan RG., Priebe W. WP744 is a novel anthracycline with enhanced activity against neuroblastoma. J Surg Res 2004, 121:187-96. 16. Kawakami K., Kawakami M., Joshi B., Puri RK. Interleuki-13-receptor-targeted cancer therapy in an immunodeficient animal
Slide 36: References
References: 28. Sattiraju A., Solingapuram Sai KK., Xuan A., Pandya DN., Almageul FG., Wadas TJ., Herpal DM., Debisnki W., Mintz A. IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget 2017, 27:42997-43007. 29. Sau S., Mondal SK., Kashaw SK., Iyer AK., Banerjee R. Combination of
Slide 37: References
References: 41. Wykosky J., Gibo DM., Stanton C., Debinski W. Interleukin -13-receptor alpha 2, EphA2 and Fos- related antigen 1 as molecular denominators of high- grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 2008; 14:199-208. 42. Yu J., Yan X., Liu Y., Zhang K.
WPD Pharmaceuticals — Investor Presentation (October 2020) on 6ix